Company | Price d* | Change d* | Volume, Avg. k, d* | Market Cap. d* | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding d* | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biotechnology Average | - - | - - | - - | 14,570.66 | 848.51 | 210.21 | -203.57 | 35.23 | 0.00 | 20.9654 | -0.39 | -1.0782 | -24.5246 | -0.09 | -0.09 | 6.7223 | - - | ||
Maximum | - - | - - | - - | 475,026.00 | 65,349.00 | 25,407.00 | 99,050.00 | 5,305.00 | 0.01 | 1,336.3467 | 6.70 | 3.0051 | 85.3485 | 0.38 | 8.35 | 37.1953 | - - | ||
Minimum | - - | - - | - - | 0.00 | 0.00 | -1,175.00 | -56,335.00 | -1,185.00 | 0.00 | -164.8536 | -8.99 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0007 | - - | ||
Nuvalent, Inc. NUVL | 95.42 | 1.33 1.41% | 251 vs. 514 | 6,660.00 | 0.00 | -44.00 | -36.00 | -330.00 | -0.6900 | -27.7942 | 0.0000 | 0.0000 | 0.0000 | -0.0659 | -0.0628 | 20.6970 | 69.00 | ||
Structure Therapeutics Inc. GPCR | 38.02 | -0.33 -0.86% | 407 vs. 676 | 2,174.00 | 0.00 | -26.00 | -34.00 | -232.00 | -0.5600 | -18.2892 | 0.0000 | 0.0000 | 0.0000 | -0.0606 | -0.0569 | 18.5046 | 57.00 | ||
Akero Therapeutics, Inc. AKRO | 34.45 | -0.42 -1.20% | 791 vs. 505 | 2,391.00 | 0.00 | -53.00 | -35.00 | -627.00 | -0.9000 | -6.6902 | 0.0000 | 0.0000 | 0.0000 | -0.0630 | -0.0585 | 29.8643 | 69.00 | ||
Arcellx, Inc. ACLX | 103.06 | 3.90 3.93% | 836 vs. 520 | 5,540.00 | 39.00 | -7.00 | -38.00 | -396.00 | -0.1400 | -122.7330 | 0.0000 | 0.9790 | -0.1834 | -0.0145 | -0.0092 | 5.3496 | 53.00 | ||
MoonLake Immunotherapeutics MLTX | 51.78 | 1.11 2.19% | 190 vs. 303 | 3,256.00 | 0.00 | -13.00 | -15.00 | -130.00 | -0.2200 | -55.6575 | 0.0000 | 0.0000 | 0.0000 | -0.0252 | -0.0242 | 61.5621 | 62.00 | ||
Cerevel Therapeutics Holdings, Inc. CERE | 44.96 | 0.33 0.74% | 15,033 vs. 2,056 | 8,191.00 | 0.00 | -131.00 | -119.00 | -1,532.00 | -0.7300 | -14.5661 | 0.0000 | 0.0000 | 0.0000 | -0.2337 | -0.1170 | 10.1215 | 182.00 |